An economic analysis of the cost of mobile units for harm reduction, naloxone distribution, and medications for opioid use disorder.

Economic evaluation Harm reduction Medications for opioid use disorder Mobile health units Opioid use disorder

Journal

Journal of substance use and addiction treatment
ISSN: 2949-8759
Titre abrégé: J Subst Use Addict Treat
Pays: United States
ID NLM: 9918541186406676

Informations de publication

Date de publication:
17 Sep 2024
Historique:
received: 10 04 2024
revised: 10 08 2024
accepted: 08 09 2024
medline: 20 9 2024
pubmed: 20 9 2024
entrez: 19 9 2024
Statut: aheadofprint

Résumé

Mobile substance use treatment units are effective approaches to increase treatment access and reduce barriers to opioid use disorder (OUD) care. However, little is known about the economic costs of maintaining and operating these units. This study aimed to estimate the economic costs of starting and maintaining mobile units providing harm reduction, overdose education and naloxone distribution (OEND), and medication for opioid use disorder (MOUD). As part of the HEALing Communities Study, four communities in Massachusetts (Bourne/Sandwich, Brockton, Gloucester, Salem) implemented mobile units offering OEND and MOUD (buprenorphine and naltrexone only); each selected different services tailored to their community. All provided MOUD linkage via telehealth, but only one offered in-person MOUD prescribing on the unit. We retrospectively collected detailed resource utilization data from invoices to estimate the direct economic costs from August 2020 through June 2022. Cost components were categorized into start-up and operating costs. We calculated total economic cost over the study period and the average monthly operating cost. Implementing a mobile unit offering OEND and MOUD required a one-time median start-up cost of $59,762 (range: $52,062-$113,671), with 80 % of those costs attributed to the vehicle purchase. The median monthly operating cost was $14,464. The largest cost category for all mobile units was personnel costs. The monthly ongoing costs varied by community settings and services: approximately $5000 for two urban communities offering OEND and MOUD linkage via telehealth (Gloucester, Salem), $28,000 for a rural community (Bourne/Sandwich), and $23,000 for an urban community also providing in-person MOUD prescribing on the unit (Brockton). The economic costs of mobile substance use treatment and harm reduction units are substantial but vary by community settings and services offered. Our results provide valuable community-level economic data to stakeholders and policymakers considering establishing and/or expanding mobile units with OEND and MOUD services. Further exploration of cost-effectiveness and efficiency should be considered across different settings.

Sections du résumé

BACKGROUND & OBJECTIVE OBJECTIVE
Mobile substance use treatment units are effective approaches to increase treatment access and reduce barriers to opioid use disorder (OUD) care. However, little is known about the economic costs of maintaining and operating these units. This study aimed to estimate the economic costs of starting and maintaining mobile units providing harm reduction, overdose education and naloxone distribution (OEND), and medication for opioid use disorder (MOUD).
METHODS METHODS
As part of the HEALing Communities Study, four communities in Massachusetts (Bourne/Sandwich, Brockton, Gloucester, Salem) implemented mobile units offering OEND and MOUD (buprenorphine and naltrexone only); each selected different services tailored to their community. All provided MOUD linkage via telehealth, but only one offered in-person MOUD prescribing on the unit. We retrospectively collected detailed resource utilization data from invoices to estimate the direct economic costs from August 2020 through June 2022. Cost components were categorized into start-up and operating costs. We calculated total economic cost over the study period and the average monthly operating cost.
RESULTS RESULTS
Implementing a mobile unit offering OEND and MOUD required a one-time median start-up cost of $59,762 (range: $52,062-$113,671), with 80 % of those costs attributed to the vehicle purchase. The median monthly operating cost was $14,464. The largest cost category for all mobile units was personnel costs. The monthly ongoing costs varied by community settings and services: approximately $5000 for two urban communities offering OEND and MOUD linkage via telehealth (Gloucester, Salem), $28,000 for a rural community (Bourne/Sandwich), and $23,000 for an urban community also providing in-person MOUD prescribing on the unit (Brockton).
CONCLUSION CONCLUSIONS
The economic costs of mobile substance use treatment and harm reduction units are substantial but vary by community settings and services offered. Our results provide valuable community-level economic data to stakeholders and policymakers considering establishing and/or expanding mobile units with OEND and MOUD services. Further exploration of cost-effectiveness and efficiency should be considered across different settings.

Identifiants

pubmed: 39299504
pii: S2949-8759(24)00229-7
doi: 10.1016/j.josat.2024.209517
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

209517

Informations de copyright

Copyright © 2024. Published by Elsevier Inc.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mathieu Castry (M)

Boston Medical Center, Section of Infectious Diseases, United States of America.

Yjuliana Tin (Y)

University of Colorado School of Medicine, Divisions of General Internal Medicine and Infectious Diseases, United States of America.

Noah M Feder (NM)

University of Pittsburgh School of Medicine, United States of America.

Nikki Lewis (N)

Boston Medical Center, Section of General Internal Medicine, United States of America.

Avik Chatterjee (A)

Boston Medical Center, Section of General Internal Medicine, United States of America; Boston University Chobanian and Avedisian School of Medicine, United States of America.

Maria Rudorf (M)

Boston Medical Center, Section of General Internal Medicine, United States of America.

Jeffrey H Samet (JH)

Boston Medical Center, Section of General Internal Medicine, United States of America; Boston University Chobanian and Avedisian School of Medicine, United States of America.

Donna Beers (D)

Boston Medical Center, Section of General Internal Medicine, United States of America.

Bethany Medley (B)

Columbia University School of Social Work, Social Intervention Group, United States of America.

Louisa Gilbert (L)

Columbia University School of Social Work, Social Intervention Group, United States of America.

Benjamin P Linas (BP)

Boston Medical Center, Section of Infectious Diseases, United States of America; Boston University Chobanian and Avedisian School of Medicine, United States of America.

Joshua A Barocas (JA)

University of Colorado School of Medicine, Divisions of General Internal Medicine and Infectious Diseases, United States of America. Electronic address: Joshua.Barocas@CUAnschutz.edu.

Classifications MeSH